Highest-materiality recent filing
Pure Bioscience raises $1.0M in private placement at $0.0553/share; directors invest
Closed private placement of 18,131,096 shares at $0.0553/share for $1.0M gross.
PURE Bioscience Q2 revenue up 13% to $443K; net loss narrows; USDA cert for PURE Clean
Net product sales Q2 $443K (up 13% YoY); six-month sales $1.15M (up 22% YoY).
Pure Bioscience shareholders approve increase in authorized shares to 250M
Approved amendment increasing authorized common shares from 200M to 250M, with 63.87% of outstanding shares voting for.
PURE Bioscience reports fiscal Q1 2026 revenue up 27% to $707K, net loss narrows to $464K
Net product sales $707K for Q1 ended Oct 31, 2025, up 27% from $555K YoY.
PURE Bioscience promotes Jeff Kitchell to President, Dolana Blount to VP of Operations
Jeffrey Kitchell appointed President and remains Corporate Secretary, effective Nov 17, 2025.
PURE Bioscience FY2025 net product sales $2.2M, net loss narrows to $2.4M from $3.4M
Net product sales $2,198K for FY2025, up 12.4% from $1,955K in FY2024.
PURE Bioscience Q3 net product sales up 11% YoY; net loss narrows to $580K
Net product sales $489K in fiscal Q3 ended Apr 30, 2025, up from $440K YoY.
PURE Bioscience Q2 net sales up 20% YoY to $391K; net loss narrows to $798K
Net product sales $391K for fiscal Q2 ended Jan 31, 2025, vs $325K a year ago (+20%).
Pure Bioscience Announces Results of 2025 Annual Meeting of Stockholders
Stockholders elected all seven director nominees with approval ranging from 95.59% to 98.18%.
PURE Bioscience Q1 FY2025 product sales $555K, down 23% YoY; net loss per share ($0.01)
Net product sales of $555K for quarter ended Oct 31, 2024, vs $718K YoY, due to budget constraints of a large end-use customer.
PURE Bioscience reports FY 2024 net loss of $3.4M; product sales up 4.5% to $1.955M
Net product sales $1.955M in FY 2024 vs $1.871M in FY 2023, up $84K (4.5%).
Pure Bioscience secures up to $3M in convertible notes; initial $500k from director Tom Y. Lee
Initial tranche of $500,000 convertible promissory note placed with director Tom Y. Lee (affiliates).
Pure Bioscience increases authorized common shares from 150M to 200M
Shareholders approved the amendment at the Feb 21, 2024 annual meeting.
PURE Bioscience Q3 net product sales $440K, net loss $857K; loss per share ($0.01)
Net product sales $440,000 for Q3 FY2024, up 8% vs $406,000 in prior-year quarter.
Pure Bioscience appoints Darin Zehr to board of directors, effective May 1, 2024
Darin Zehr appointed as independent director; will serve on Audit and Compensation Committees.
Pure Bioscience raises $500K via convertible notes from director; up to $3M total
Initial $500,000 private placement of convertible promissory notes to accredited investors, including board member Tom Y. Lee.
PURE Bioscience Q2 net product sales $325K, net loss $1.0M; shifting to distributor model
Net product sales $325K in Q2 FY2024, down 18% from $396K YoY; net loss $1.002M vs $1.060M.
Pure Bioscience shareholders approve increase in authorized shares to 200M
All six director nominees elected with 97-99% of votes cast; terms until next annual meeting.
On May 1, 2024, the Board of Directors (the “Board”) of Pure Bioscience, Inc. (the “Company”) authorized and appointed Darin Zehr, as a member of the Board.
Max materiality 0.70 · Median 0.55 · Most common event earnings